Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

StatusRecruiting
PhasePhase 3
SponsorAmgen
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 37 → 45 locations
    • Eligibility criteria expanded, about 24 words
    • Secondary endpoints: details revised at 2 of 13 entries
  2. Re-verified, no change to tracked fieldsv4
  3. Trial sites expanded: 24 → 37 locationsv3
  4. Recruitment opened
    • Trial sites expanded: 0 → 24 locations
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Amgen
169 trials monitored
See 11 trials at risk
Diabetes
5,101 trials monitored
See 233 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
Type 2 Diabetes
2,236 trials monitored
See 113 trials at risk
The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).
Trial Details
NCT Number NCT07684144
Lead Sponsor Amgen
Conditions
(from sponsor)		 Obesity, Overweight, Diabetes Mellitus, Type 2
Related terms Diabetes Mellitus, Type 2, Obesity, Overweight
Enrollment 950 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov